Research finds limited publications and dearth of information about side effects
Michelle Dalton, ELS
Findings from the PERMEATE study used novel diagnostics to quantify response to intravitreal injections
Alzheimer’s disease leads to severe cognitive dysfunction and eventual death; by 2050 it is expected to affect more than 115 million people worldwide. From time of diagnosis until death the average survival time is just under 5 years.
When used one week after injection, optical coherence tomography angiography can help clinicians determine how effective their treatment has been on neovascular membrane reperfusion.
Using a specific anti-vascular endothelial growth factor (VEGF) drug in patients with moderately severe to severe nonproliferative diabetic retinopathy (NPDR) can result i
Light-activated AU-011 has the potential to be the first targeted therapy ever developed for the primary treatment of ocular
Factoring in that patients require continual and constant monitoring, maintenance
Tybee—a phase II clinical trial evaluating suprachoroidal CLS-TA used with intravitreally administered aflibercept in patients with diabetic macular edema (DME) over a 6-month evaluation period—has met both primary and secondary endpoints
When it comes to first-line anti-vascular endothelial growth factor (VEGF) agents for the treatment of age-related macular degeneration (AMD), the overwhelming majority of retina specialists in Africa/Middle East (n = 198) and the United
A short course of oral mifepristone may reduce or improve subretinal fluid and improve best-corrected visual acuity (BCVA) in patients with chronic or recurrent central serous chorioretinopathy (CSC), said Roger Goldberg, MD, MBA, with Ba